A new multicenter, single-arm, open-label study is the first to exclusively assess bleeding complications in patients undergoing high-risk percutaneous coronary interventions (PCI) with Impella with independent adjudication via a clinical events adjudication committee and will gather meaningful real-world data based on contemporary practice.